Delenex completes its management team
Thomas Jung becomes chief medical officer
A board certified dermatologist, Jung has led research work in immunology at the Novartis Research Institute in Vienna, Austria, then spent nine years at Novartis in Basel, Switzerland.
In January 2008 he took leadership of the Ilaris development team, until its first marketing approval in 2009. Since then, he was part of the senior leadership team at the Novartis Institute for Biomedical Research (NIBR), most recently as EU Head of Translational Medicine.
Delenex was created in September 2009 as a spin-off from ESBATech (now part of Alcon, the eye care division of Novartis), and is the exclusive licensee for any non-ophthalmic uses of ESBATech's products and IPR pre-dating the spin-off.
Eric de La Fortelle, ceo of Delenex, said: ‘With the arrival of an experienced clinician, initially trained in dermatology but with significant clinical development experience in several other therapeutic areas, notably autoimmunity, gastroenterology, respiratory, neurosciences and musculoskeletal disorders, Delenex is able to do full justice to its powerful discovery platform, and implement the best clinical programmes to bring its major new compounds to clinical proof of concept.’
You may also like
Pharma 5.0
Excelsior Sciences raises $95m for AI-powered small molecule discovery and manufacturing
Deerfield Management, Khosla Ventures and Sofinnova Partners co-lead Series A fundraising for Excelsior Sciences to accelerate drug discovery and clinical development while supporting pharma reshoring
Contamination Control
Eurofins launches first GMP-compliant PFAS screening solution for the medical device industry
Eurofins Medical Device Services North America has introduced the industry’s first GMP PFAS testing and screening platform, helping manufacturers meet tightening global regulations and safeguard device and patient safety